CERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cerus Corp (CERS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows a bullish technical trend, positive analyst sentiment, and a strong growth trajectory in revenue, despite short-term financial challenges. The discounted valuation and potential for scalability through partnerships make it an attractive long-term investment.
The technical indicators suggest a bullish trend. The MACD is positive and expanding, the RSI is neutral, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with resistance at 2.625, indicating potential for further upward movement.
TD Cowen's positive analyst rating with a price target of $5, citing the Intercept Fibrinogen Complex franchise as a long-term growth engine.
Revenue growth of 18.91% YoY in Q3
Bullish technical indicators and discounted valuation.
Net income dropped significantly (-99.35% YoY) in Q3
EPS fell to 0, down 100% YoY.
Gross margin slightly declined (-2.71% YoY).
In Q3 2025, Cerus Corp reported an 18.91% YoY increase in revenue to $60.24M. However, net income dropped to -$19K (-99.35% YoY), and EPS fell to 0 (-100% YoY). Gross margin also declined slightly to 59.23% (-2.71% YoY).
TD Cowen has a Buy rating on CERS with a price target of $5, citing confidence in the company's double-digit revenue growth trajectory and the scalability of its products through new partnerships.
